Welcure Pharmaceuticals Pvt Ltd

AUDITED FINANCIAL RESULTS COMPANY FOR THE LAST THREE FINANCIAL YEARS

	(Amount in ₹ except per share data)			
	Financial Year 2023	Financial Year 2022	Financial Year 2021	
	Standalone	Standalone	Standalone	
Reserves (Excluding	6,947,049	7,362,340	7,034,745	
Revaluation Reserve) Sales	Nil	Nil	Nil	
Profit/(Loss) after Tax	(415,921)	327,595327	350,549	
Earnings per Share (Basic) (Face Value of Rs.10)	(1.64)	1.29	1.39	
Earnings per Share (Diluted) (Face Value of Rs.10)	(1.64)	1.29	1.39	
Net Asset Value	37.45 millions	39.10 millions	37.80 millions	

Significant Notes of the Auditors:

Our turnover as on 31st March, 2023 is Rs. Nil.

Akome Lifecare Pvt Ltd

AUDITED FINANCIAL RESULTS OF THE COMPANY FOR THE LAST THREE FINANCIAL YEARS

(Amount in Rs. except per share data)

	Financial Year March 2023		
	Standalone		
Reserves (Excluding Revaluation Reserve)	30,788,308		
Sales	7,884,430		
Profit/(Loss) after Tax	30,788,308		
Earnings per Share (Basic) (Face Value of Rs.10/-)	3078.83		
Earnings per Share (Diluted) (Face Value of Rs.10/-)	3078.83		
Net Asset Value	30888308		

Significant Notes of the Auditors:

NIL

Our turnover as on 31^{st} March, 2023 is Rs. 7,884,430.

Akums Foundation

AUDITED FINANCIAL RESULTS COMPANY FOR THE LAST THREE FINANCIAL YEARS

	Financial Year 31 st March, 2023		Financial Year 31 st March,2022		Financial Year 31 st March, 2021	
	Standalo		Standalo	Consolidat	Standalo	Consolidat
	ne		ne	ed	ne	ed
Reserves	2,619,529	NIL	6,314,678	NIL	(36,254)	NIL
(Excluding						
Revaluation						
Reserve)						
Sales	NIL	NIL	NIL	NIL	NIL	NIL
Profit/(Loss)	(47,95,149	NIL	63,50,932	NIL	(26,501)	NIL
after Tax)					
Earnings per	(47.95)	NIL	63.50	NIL	(2.6)	NIL
Share (Basic)						
(Face Value						
of ₹10)						
Earnings per	(47.95)	NIL	63.50	NIL	(2.6)	NIL
Share						
(Diluted)						
(Face Value						
of ₹ 10)						
Net Asset	1,619,529	NIL	7,314,678	NIL	63,746	NIL
Value						

(Amount in Rs. except per share data)

Significant Notes of the Auditors:

Our turnover as on 31^{st} March, 2023 is Rs. 65,439,476

American Remedies Lifesciences Ltd

AUDITED FINANCIAL RESULTS OF THE COMPANY FOR THE LAST THREE FINANCIAL YEARS

	Financial Year 2023	Financial Year 2022	Financial Year 2021		
	Standalone	Standalone	Standalone		
Reserves (Excluding	(45,694)	(37,445)	(20,152)		
Revaluation Reserve)					
Sales	Nil	Nil	15,300		
Profit/(Loss) after Tax	(8249)	(17,293)	(20,152)		
Earnings per Share	(1.18)	2.47	(6.18)		
(Basic) (Face Value of					
Rs.10)					
Earnings per Share	(1.18)	2.47	(6.18)		
(Diluted) (Face Value			· · ·		
of Rs.10)					
Net Asset Value	24,306	32,555	49,848		

(Amount in Rs. except per share data)

Significant Notes of the Auditors:

NIL

Our turnover as on 31st March, 2023 is NIL.